An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug–Drug Interaction Study

BACKGROUND: Gilteritinib, a novel, potent FLT3/AXL inhibitor, was recently approved in Japan and USA for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. PURPOSE AND METHODS: In this study, we aimed to develop and validate a sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiong, Chen, Zhe, Chen, Dingwen, Ye, Xia-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266109/
https://www.ncbi.nlm.nih.gov/pubmed/32546970
http://dx.doi.org/10.2147/DDDT.S243760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266109/
https://www.ncbi.nlm.nih.gov/pubmed/32546970
http://dx.doi.org/10.2147/DDDT.S243760

Ejemplares similares